Based in the United States, Anida Pharma is a startup.
Anida Pharma is developing first-in-class therapeutics that leverage endogenous protective mechanisms to prevent progressive eye diseases. Its lead candidate, AP-001, is a modified form of neuroprotectin D1 designed for topical ocular administration (eye drops) to treat corneal and retinal degenerative conditions.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.